Healthcare / BiotechnologyNasdaqCM
$1.25
-0.05 (-3.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$86M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-176.1%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-10.4M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-10.4M | $-10.4M | $-16.5M | $-13.1M | $-854147.00 |
| EBITDA | $-10.4M | $-10.4M | $-12.2M | $-11.4M | $-854147.00 |
| EPS | — | — | -0.56 | -0.44 | -0.03 |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | 0.03 | — |
| Current Ratio | 7.00 | 7.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-5.1M | $-3.9M | $-468661.00 |
| Returns | |||||
| ROE | -176.1% | -176.1% | -2571.0% | -380.2% | 91.1% |
| Valuation | |||||
| P/B | 7.27 | 7.27 | 207.64 | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | -26.8% | -1430.4% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.56 → n/d
Residual
-35.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.